202 related articles for article (PubMed ID: 36786972)
1. Refractory nonfunctioning pituitary adenomas.
Kolitz T; Greenman Y
Pituitary; 2023 Jun; 26(3):278-280. PubMed ID: 36786972
[TBL] [Abstract][Full Text] [Related]
2. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
3. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
Widhalm G; Wolfsberger S; Preusser M; Woehrer A; Kotter MR; Czech T; Marosi C; Knosp E
Cancer; 2009 Mar; 115(5):1070-80. PubMed ID: 19156926
[TBL] [Abstract][Full Text] [Related]
4. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile.
Batista RL; Trarbach EB; Marques MD; Cescato VA; da Silva GO; Herkenhoff CGB; Cunha-Neto MB; Musolino NR
World Neurosurg; 2018 Dec; 120():e241-e246. PubMed ID: 30138730
[TBL] [Abstract][Full Text] [Related]
5. Medical therapy for refractory pituitary adenomas.
Geer EB
Pituitary; 2023 Jun; 26(3):303-306. PubMed ID: 37115295
[TBL] [Abstract][Full Text] [Related]
6. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
7. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Lenders N; McCormack A
Pituitary; 2018 Apr; 21(2):217-229. PubMed ID: 29299820
[TBL] [Abstract][Full Text] [Related]
8. Subclinical hyperfunctioning pituitary adenomas: the silent tumors.
Cooper O; Melmed S
Best Pract Res Clin Endocrinol Metab; 2012 Aug; 26(4):447-60. PubMed ID: 22863387
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in aggressive pituitary adenomas and carcinomas.
Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Elbelt U; Schlaffer SM; Buchfelder M; Knappe UJ; Vila G; Micko A; Deutschbein T; Unger N; Lammert A; Topuzoglu-Müller T; Bojunga J; Droste M; Johanssen S; Kolenda H; Ritzel K; Buslei R; Strasburger CJ; Petersenn S; Honegger J
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31746334
[TBL] [Abstract][Full Text] [Related]
12. Use of temozolomide in aggressive pituitary tumors: case report.
Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
[TBL] [Abstract][Full Text] [Related]
13. Treatment of pituitary neoplasms with temozolomide: a review.
Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
Dillard TH; Gultekin SH; Delashaw JB; Yedinak CG; Neuwelt EA; Fleseriu M
Pituitary; 2011 Mar; 14(1):80-91. PubMed ID: 20972839
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
[TBL] [Abstract][Full Text] [Related]
16. 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update.
Syro LV; Rotondo F; Ortiz LD; Kovacs K
Endocr Relat Cancer; 2018 Aug; 25(8):T159-T169. PubMed ID: 29535142
[TBL] [Abstract][Full Text] [Related]
17. Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series.
Padovan M; Cerretti G; Caccese M; Barbot M; Bergo E; Occhi G; Scaroni C; Lombardi G; Ceccato F
Expert Rev Endocrinol Metab; 2023 Mar; 18(2):181-198. PubMed ID: 36876325
[TBL] [Abstract][Full Text] [Related]
18. Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.
Ghazi AA; Rotondo F; Kovacs K; Amirbaigloo A; Syro LV; Fathalla H; Di Ieva A; Cusimano MD
Endocr Pathol; 2015 May; 26(2):135-9. PubMed ID: 25716461
[TBL] [Abstract][Full Text] [Related]
19. Nonfunctioning pituitary adenomas in pediatric and adolescent patients: a clinical analysis of a series of 14 patients.
Wang H; Wang R; Hu T; Wang Z; Duan Y; Han S; Wu A
J Neurooncol; 2020 May; 148(1):179-186. PubMed ID: 32333187
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]